Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul;398(7):9125-9138.
doi: 10.1007/s00210-025-03854-0. Epub 2025 Feb 5.

Inhibition of protein phosphatases attenuates A1-adenosine receptor-stimulation induced negative inotropic effects of cAMP-increasing agents in the isolated human atrium

Affiliations

Inhibition of protein phosphatases attenuates A1-adenosine receptor-stimulation induced negative inotropic effects of cAMP-increasing agents in the isolated human atrium

Rebecca Schwarz et al. Naunyn Schmiedebergs Arch Pharmacol. 2025 Jul.

Abstract

N6-(R)-Phenylisopropyladenosine (R-PIA), an agonist at A1-adenosine receptors, alone exerts negative inotropic effects (NIE) in the human atrium. This NIE is augmented in the presence of cAMP-increasing agonists like phosphodiesterase inhibitors (cilostamide, rolipram) or a direct activator of adenylyl cyclase (forskolin). Cantharidin inhibits protein phosphatases 1 and 2A (PP1, PP2A). We hypothesized that cantharidin would attenuate this NIE of R-PIA in the presence of cilostamide or forskolin. During open heart surgery (patients were suffering from severe coronary heart disease), isolated human atrial preparations (HAP) were obtained. These HAP were mounted in organ baths and electrically stimulated (1 Hz). For comparison, we studied isolated electrically stimulated (1 Hz) left atrial preparations (LA) from wild type mice. We noted that R-PIA exerted negative inotropic effects in LA and HAP in the presence of cilostamide or rolipram and forskolin that were attenuated by cantharidin. We hypothesize that R-PIA in the presence of phosphodiesterase inhibitors or forskolin stimulates PP in the human atrium. Hence, R-PIA acts, at least in part, by stimulating PP in HAP.

Keywords: Adenosine receptor; CAMP; Cantharidin; Human atrium; Phosphatases.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethical approval: The investigation conformed to the Guide for the Care and Use of Laboratory Animals as published by the National Research Council (2011). The animals were handled and maintained according to the approved protocols of the Animal Welfare Committee of the University of Halle-Wittenberg, Halle, Germany. Humans: This study complies with the Declaration of Helsinki and has been approved by the local ethics committee. Consent to participate: Informed consent was obtained from all patients included in the study. Consent for publication: All authors declare that they have seen and approved the submitted version of this manuscript. Competing interests: The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Phosphodiesterase (PDE) isoenzyme inhibition (by rolipram or cilostamide) and forskolin increase cAMP levels in the human atrium are depicted. This cAMP activates cAMP-dependent protein kinases (PKA). PKA then phosphorylates regulatory proteins in the human atrium. Cardiac relaxation is brought about by phosphorylation of phospholamban (PLB). Cardiac contraction is in part mediated by ryanodine receptors (RyR). The activities of protein phosphatases (PP) PP1 and PP2A are inhibited by cantharidin. R-PIA via stimulation of A1-adenosine receptors may inhibit the enzymatic activity of adenylyl cyclase (AC) via a pertussis-toxin-sensitive G-protein (Gi) and may open potassium channels (PC) in the sarcolemma or may close L-type calcium ion (Ca2+) channels (LTCC) and may directly or indirectly activate PP
Fig. 2
Fig. 2
Effects of R-PIA in the presence of rolipram on contractile parameters in left and right mouse atrium in the presence or absence of cantharidin. A Original recording of the effect of R-PIA in the presence of rolipram on the force of contraction in milli Newton (mN, Ordinate) over time in minutes (min, Abscissa). B Original recording of the effect of R-PIA in the presence of rolipram on the force of contraction in the additional presence of 30 µM cantharidin (CANT) in milli Newton (mN, Ordinate) over time in minutes (min, Abscissa). C Diagram for the negative inotropic effect of R-PIA in the presence of rolipram alone or the additional presence of cantharidin (30 µM) in isolated electrically driven mouse left atrial preparations. Ordinates and abscissa give the force of contraction in % of pre-drug value or applied concentration of R-PIA, respectively. The asterisk (*) and plus sign ( +) indicate the first significant difference versus 30 µM cantharidin or time-matched control values (Ctr2) or R-PIA in the presence of cantharidin, respectively. Number (n) indicates the number of experiments. Ctr1 indicates pre-drug value. Ctr2 (100%) indicates plus/minus cantharidin. D Line diagram of the effects of R-PIA in the presence of rolipram or in the additional presence of cantharidin (30 µM) on rate of tension development in isolated electrically driven mouse left atrial preparations. Ordinate and abscissa give the rate of tension development (dF/dtmax) in % of pre-drug value or applied concentration of R-PIA, respectively. The asterisk (*) and plus sign ( +) indicate the first significant difference versus 30 µM cantharidin or time-matched control values (Ctr2) or R-PIA in the presence of cantharidin, respectively. Number (n) indicates the number of experiments. Ctr1 indicates pre-drug value. Ctr2 (100%) indicates plus/minus cantharidin. E Line diagram of the effects of R-PIA in the presence of rolipram or in the additional presence of cantharidin (30 µM) on rate of tension relaxation in isolated electrically driven mouse left atrial preparations. Ordinate and abscissa give the rate of tension relaxation (dF/dtmin) in % of pre-drug value or applied concentration of R-PIA, respectively. The asterisk (*) and plus sign ( +) indicate the first significant difference versus 30 µM cantharidin or time-matched control values (Ctr2) or R-PIA in the presence of cantharidin, respectively. Number (n) indicates the number of experiments. Ctr1 indicates pre-drug value. Ctr2 (100%) indicates plus/minus cantharidin
Fig. 3
Fig. 3
Effects of R-PIA in the presence of forskolin on contractile parameters in left and right mouse atrium in the presence or absence of cantharidin. A Original recording of the effect of R-PIA (1 µM) in the presence of forskolin (1 µM) on the force of contraction in milli Newton (mN, Ordinate) over time in minutes (min, Abscissa). B Original recording of the effect of R-PIA (1 µM) in the presence of forskolin (1 µM) on the force of contraction in the additional presence of cantharidin (30 µM) in milli Newton (mN, Ordinate) over time in minutes (min, Abscissa). C Line diagram of the negative inotropic effect of R-PIA (1 µM) in the presence of forskolin (1 µM) or with first applied cantharidin (30 µM) in isolated electrically driven left atrial preparations. Ordinate and abscissa give the force of contraction in % of pre-drug value or applied concentration of R-PIA (1 µM), respectively. The asterisk (*) and number sign (#) indicate the first significant difference versus 30 µM cantharidin or time-matched control values (Ctr2) or R-PIA (1 µM) in the presence of cantharidin, respectively. Number (n) indicates the number of experiments. Ctr1 indicates pre-drug value. Ctr2 (100%) indicates plus/minus cantharidin. D Line diagram of the effects of R-PIA (1 µM) alone or in additional presence of cantharidin (30 µM) on the rate of tension development in isolated electrically driven mouse left atrial preparations. Ordinate and abscissa give the rate of tension development (dF/dtmax) in % of pre-drug value or applied concentration of R-PIA, respectively. The asterisk (*) and number sign (#) indicate the first significant difference versus 30 µM cantharidin or time-matched control values (Ctr2) or R-PIA in the presence of cantharidin, respectively. Number (n) indicates the number of experiments. Ctr1 indicates pre-drug value. Ctr2 (100%) indicates plus/minus cantharidin. E Line diagram of the effects of R-PIA (1 µM) in the presence of forskolin (1 µM) or in additional presence of cantharidin (30 µM) on rate of tension relaxation in isolated electrically driven human right atrial preparations. Ordinate and abscissa give the rate of tension relaxation (dF/dtmin) in % of pre-drug value or applied concentration of R-PIA, respectively. The asterisk (*) and number sign (#) indicate the first significant difference versus 30 µM cantharidin or time-matched control values (Ctr2) or R-PIA in the presence of cantharidin, respectively. Number (n) indicates the number of experiments. Ctr1 indicates pre-drug value. Ctr2 (100%) indicates plus/minus cantharidin
Fig. 4
Fig. 4
Cantharidin attenuates the negative inotropic effect of R-PIA of cilostamide on contractile parameters in the human right atrium. A Original recording of the effect of R-PIA (1 µM) and 1 µM cilostamide on the force of contraction in milli Newton (mN, Ordinate) over time in minutes (min, Abscissa). B Original recording of the effect of R-PIA and 1 µM cilostamide on the force of contraction in the presence of 100 µM cantharidin (CANT) in milli Newton (mN, Ordinate) over time in minutes (min, Abscissa). C Line diagram of the negative inotropic effect of R-PIA and 1 µM cilostamide or after first applied cantharidin (100 µM) in isolated electrically driven mouse left atrial preparations. Ordinates and abscissa give the force of contraction in % of pre-drug value or applied concentration of R-PIA, respectively. The asterisk (*) and plus sign ( +) indicate the first significant difference versus 100 µM cantharidin or time-matched control values (Ctr2) or R-PIA in the presence of cantharidin, respectively. Number (n) indicates the number of experiments. Ctr1 indicates pre-drug value. Ctr2 (100%) indicates plus/minus cantharidin. D Diagram of the effects of R-PIA in the presence and 1 µM cilostamide or in additional presence of cantharidin (100 µM) on rate of tension development in isolated electrically driven mouse left atrial preparations. Ordinate and abscissa give the rate of tension development (dF/dtmax) in % of pre-drug value or applied concentration of R-PIA, respectively. The asterisk (*) and plus sign ( +) indicate the first significant difference versus 100 µM cantharidin or time-matched control values (Ctr2) or R-PIA in the presence of cantharidin, respectively. Number (n) indicates the number of experiments. Ctr1 indicates pre-drug value. Ctr2 (100%) indicates plus/minus cantharidin
Fig. 5
Fig. 5
Cantharidin does not attenuate the negative inotropic effect of R-PIA in the presence of forskolin on contractile parameters in the human right atrium. A Original recording of the effect of R-PIA (1 µM) in the presence of forskolin (1 µM) on the force of contraction in milli Newton (mN, Ordinate) over time in minutes (min, Abscissa). B Original recording of the effect of R-PIA (1 µM) in the presence of forskolin (1 µM) on the force of contraction in the additional presence of cantharidin (100 µM) in milli Newton (mN, Ordinate) over time in minutes (min, Abscissa). C Line diagram of the negative inotropic effect of R-PIA (1 µM) in the presence of forskolin (1 µM) or with first applied cantharidin (100 µM) in isolated electrically driven human right atrial preparations. Ordinate and abscissa give the force of contraction in % of pre-drug value or applied concentration of R-PIA, respectively. The asterisk (*) and number sign (#) indicate the first significant difference versus 100 µM cantharidin or time-matched control values (Ctr2) or R-PIA in the presence of cantharidin, respectively. Number (n) indicates the number of experiments. Ctr1 indicates pre-drug value. Ctr2 (100%) indicates plus/minus cantharidin. D Line diagram of the effects of R-PIA (1 µM) in the presence of forskolin (1 µM) or in additional presence of cantharidin (100 µM) on rate of tension development in isolated electrically driven human right atrial preparations. Ordinate and abscissa give the rate of tension development (dF/dtmax) in % of pre-drug value or applied concentration of R-PIA, respectively. The asterisk (*) and number sign (#) indicate the first significant difference versus 100 µM cantharidin or time-matched control values (Ctr2) or R-PIA in the presence of cantharidin, respectively. Number (n) indicates the number of experiments. Ctr1 indicates pre-drug value. Ctr2 (100%) indicates plus/minus cantharidin. E Line diagram of the effects of R-PIA (1 µM) in the presence of forskolin (1 µM) or in additional presence of cantharidin (100 µM) on rate of tension relaxation in isolated electrically driven human right atrial preparations. Ordinate and abscissa give the rate of tension relaxation (dF/dtmin) in % of pre-drug value or applied concentration of R-PIA, respectively. The asterisk (*) and number sign (#) indicate the first significant difference versus 100 µM cantharidin or time-matched control values (Ctr2) or R-PIA in the presence of cantharidin, respectively. Number (n) indicates the number of experiments. Ctr1 indicates pre-drug value. Ctr2 (100%) indicates plus/minus cantharidin

Similar articles

References

    1. Ahmad Z, Green FJ, Subuhi HS, Watanabe AM (1989) Autonomic regulation of type 1 protein phosphatase in cardiac muscle. J Biol Chem 264(7):3859–3863 - PubMed
    1. Bartel S, Stein B, Eschenhagen T, Mende U, Neumann J, Schmitz W, Krause EG, Karczewski P, Scholz H (1996) Protein phosphorylation in isolated trabeculae from nonfailing and failing human hearts. Mol Cell Biochem. 157(1–2):171–9. 10.1007/BF00227896 - PubMed
    1. Baumann G, Felix SB, Schrader J, Heidecke CD, Riess G, Erhardt WD, Ludwig L, Loher U, Sebening F, Blömer H (1981) Cardiac contractile and metabolic effects mediated via the myocardial H2-receptor adenylate cyclase system. Characterization of two new specific H2-receptor agonists, impromidine and dimaprit, in the guinea pig and human myocardium. Res Exp Med (Berl) 179(1):81–98. 10.1007/BF01852128 - PubMed
    1. Belevych AE, Nulton-Persson A, Sims C (2001) Harvey RD Role of tyrosine kinase activity in alpha-adrenergic inhibition of the beta-adrenergically regulated L-type Ca(2+) current in guinea-pig ventricular myocytes. J Physiol 537(Pt 3):779–792. 10.1111/j.1469-7793.2001.00779.x - PMC - PubMed
    1. Böhm M, Meyer W, Mügge A, Schmitz W, Scholz H (1985a) Functional evidence for the existence of adenosine receptors in the human heart. Eur J Pharmacol 116(3):323–326. 10.1016/0014-2999(85)90170-0 - PubMed

MeSH terms

LinkOut - more resources